"What's interesting about the complete response is what's not in there," Carr writes. "FDA was pretty focused on only a few issues specific to lorcaserin. In a sense, could be a good sign overall for weight loss drugs. Of course, [Vivus'] Qnexa and [Orexigen's] Contrave have their own issues." So maybe this was a muted win for the other obesity players -- although I wouldn't hold my breath.